Hypertension-focused Mineralys Therapeutics announced its upsized initial public offering Thursday, putting 12,000,000 shares of common stock for sale for $16.00 per share – and infusing a little hope into a bear biopharma market.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,